Changeflow GovPing Healthcare & Life Sciences Atai Therapeutics US12606525B2 Patent Grant
Routine Rule Added Final

Atai Therapeutics US12606525B2 Patent Grant

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12606525B2 to Atai Therapeutics, Inc. covering dimethyltryptamine analogues as nitric oxide delivery drugs, specifically compounds of Formula (I) or (II) and pharmaceutical compositions comprising those compounds. The patent was granted on April 21, 2026, with application number 18657306 and 34 claims.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12606525B2 to Atai Therapeutics, Inc. for dimethyltryptamine analogues as nitric oxide delivery drugs, classified under CPC C07D 209/16. The patent covers compounds of Formula (I) or (II) and pharmaceutical compositions comprising those compounds.

Patent holders and pharmaceutical companies developing nitric oxide-related therapeutics should be aware that this patent may encumber freedom-to-operate in this chemical space. Competitors researching DMT analogues for therapeutic applications should conduct freedom-to-operate analyses and consider potential licensing arrangements.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Dimethyltryptamine analogues as nitric oxide delivery drugs

Grant US12606525B2 Kind: B2 Apr 21, 2026

Assignee

Atai Therapeutics, Inc.

Inventors

Robert B. Perni, Glenn Short, Tanweer A. Khan

Abstract

Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

CPC Classifications

C07D 209/16

Filing Date

2024-05-07

Application No.

18657306

Claims

34

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606525B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting Drug development IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!